Efficacy of indobufen versus aspirin in the treatment of unstable angina pectoris and their effects on uric acid metabolism and treatment safety in patients
10.3760/cma.j.cn341190-20250306-00293
- VernacularTitle:吲哚布芬与阿司匹林治疗不稳定型心绞痛疗效及对患者尿酸代谢、安全性的影响比较
- Author:
Qiying ZHAO
1
;
Yu ZHAO
1
Author Information
1. 诸暨市第六人民医院普内科，诸暨 311801
- Publication Type:Journal Article
- Keywords:
Coronary disease;
Angina,unstable;
Treatment outcome;
Uric acid;
Drug-related side effects and adverse reactions;
Aspirin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2025;32(9):1374-1379
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of indobufen versus aspirin in the treatment of unstable angina pectoris (UAP) and their effects on uric acid metabolism and treatment safety in patients. Methods:A total of 200 patients with UAP who received treatment at the Sixth People's Hospital of Zhuji from January 2023 to April 2024 were included in this prospective study. The patients were randomly divided into a control group and an observation group, with 100 patients in each group. All patients received standard treatment, including lipid-lowering, antihypertensive, and coronary dilation therapies. For anticoagulation treatment, the control group received dual antiplatelet therapy with aspirin and ticagrelor, while the observation group received dual antiplatelet therapy with indobufen and ticagrelor. After 6 months of treatment, the clinical efficacy, coagulation function, blood pressure, blood lipid levels, and uric acid metabolism were compared between the two groups. Adverse reactions occurring during the treatment period were also monitored.Results:The overall effective rate in the observation group was not significantly different from that in the control group [93.00% (93/100) vs. 91.00% (91/100), χ2 = 0.63, P > 0.05]. There were no statistically significant differences in coagulation function, blood pressure, or lipid metabolism indicators between the two groups after treatment (all P > 0.05). However, the increase in uric acid levels in the observation group after treatment was significantly lower than that in the control group [(4.32 ± 1.27) μmol/L vs. (35.94 ± 5.52) μmol/L, t = 54.28, P < 0.001]. During the treatment period, the incidences of gastrointestinal mucosal damage and bleeding in the observation group were significantly lower than those in the control group ( χ2 = 4.30, 4.19, both P < 0.05). Conclusions:Indobufen and aspirin have demonstrated good clinical efficacy in long-term anticoagulant therapy for UAP. Compared with aspirin, indobufen more effectively reduces the risk of elevated uric acid levels in patients and decreases the risk of gastrointestinal mucosal damage and bleeding, thereby enhancing long-term medication safety.
